Neurocrine Biosciences | الأصول



Assets تغيير تاريخ
AbbVie USD 136.17B 1B 2025-03
Acadia Pharmaceuticals USD 1.23B 93.19M 2025-06
Agios Pharmaceuticals USD 1.47B 84.28M 2025-06
ALKERMES USD 2.25B 170.83M 2025-06
Alnylam Pharmaceuticals USD 4.57B 352.21M 2025-06
Amgen USD 87.9B 1.47B 2025-06
Biogen USD 28.33B 297.1M 2025-06
BioMarin Pharmaceutical USD 7.46B 309.33M 2025-06
Cytokinetics USD 1.23B 38.42M 2025-06
Dynavax Technologies USD 918.45M 27.48M 2025-06
Exelixis USD 2.68B 159.17M 2025-07
Gilead Sciences USD 55.72B 713M 2025-06
Halozyme Therapeutics USD 2.05B 142.63M 2025-06
Incyte USD 5.82B 71.99M 2025-06
Ionis Pharmaceuticals USD 2.99B 172.18M 2025-06
Neurocrine Biosciences USD 3.89B 202.1M 2025-06
Pfizer USD 206.1B 1.93B 2025-06
Prothena USD 547.11M 48.15M 2024-12
Regeneron Pharmaceuticals USD 38.22B 674M 2025-06
Repligen USD 2.85B 22.48M 2025-03
Sarepta Therapeutics USD 3.68B 214.43M 2025-06
Teva Pharmaceutical Industries USD 40.13B 1.72B 2025-06
Ultragenyx Pharmaceutical USD 1.31B 5.66M 2025-06
Vertex Pharmaceuticals USD 24.04B 1.16B 2025-06


Neurocrine Biosciences الأصول - القيم الحالية، والبيانات التاريخية، والتنبؤات والإحصاءات والرسوم البيانية والتقويم الاقتصادي - Aug 2025.